Novel Synthetic Steroid Derivatives: Target Prediction and Biological Evaluation of Antiandrogenic Activity
December 2025
in “
Current Issues in Molecular Biology
”
New to Spironolactone? There is a guide in the encyclopedia. Read the guide → Studysummary This study evaluated novel steroids' potential as future hormonal therapies for neuroprotection in glucose disorders, but emphasized that further research is needed to optimize androgen antagonist use in the context of COVID-19 progression.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study explores novel synthetic steroid derivatives derived from 16-dehydropregnenolone acetate for their antiandrogenic activity and potential neuroprotective effects. These derivatives, particularly those with an electrophilic center, efficiently interact with the 5α-reductase enzyme, suggesting neuroprotection in hypoglycemic conditions. The compounds were synthesized with yields of 30%-80% and showed good inhibition of the 5α-reductase enzyme, indicating promise for future hormonal therapies, especially in glucose disorder contexts. The research also highlights the potential of these steroids in treating androgen-dependent conditions like prostate cancer and benign prostatic hyperplasia, as well as their role in reducing COVID-19 severity. A meta-analysis of 21 studies with 9,922 patients showed a significant reduction in mortality among those receiving steroids. The study involved 20 male Wistar rats and assessed various biomarkers, demonstrating significant 5α-reductase inhibitory activity compared to the spironolactone control group. Further research is necessary to optimize their use in clinical settings and explore their potential in mitigating severe COVID-19 outcomes.
